Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- The experimental phases of the study were performed between 12 May 2008 and 28 August 2008.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to GLP and in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do no effect the quality of the relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Date of GLP Inspection: 19-21 July 2011. Date of Signature: 31 August 2011
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Details on test material:
- Sponsor's identification: Diurea thickener 8
Description: Light brown solid
Purity: 95 %
Batch number: Not supplied
Date received: 12 September 2011
Expiry date: Not supplied
Storage conditions: Room temperature in the dark
Constituent 1
Method
- Target gene:
- Not applicable.
Species / strain
- Species / strain / cell type:
- lymphocytes: human
- Details on mammalian cell type (if applicable):
- For each experiment, sufficient whole blood was drawn from the peripheral circulation of a volunteer who had been previously screened for suitabilityThe volunteer had not been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- phenobarbitone and beta-naphthoflavone induced rat liver, S9
- Test concentrations with justification for top dose:
- Cell Growth Inhibition Test:
4(20)-hour without S9: 0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 µg/ml.
4(20)-hour with S9: 0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 µg/ml.
20-hour without S9: 0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 µg/ml.
Experiment 1
i) 4-hour exposure to the test item without S9-mix followed by 20-hour culture in treatment-free media prior to cell harvest. The dose range of test item used was 0, 2, 4, 8, 16, 24 and 32 µg/ml.
ii) 4-hour exposure to the test item with S9-mix followed by 20-hour culture in treatment-free media prior to cell harvest. The dose range of test item used was 0, 2, 4, 8, 16, 24 and 32 µg/ml.
Experiment 2
i) 24-hour continuous exposure to the test item without S9-mix prior to cell harvest. The dose range of test item used was 0, 2, 4, 8, 12, 16 and 24 µg/ml.
ii) 4-hour exposure to the test item with S9-mix followed by 20-hour culture in treatment-free media prior to cell harvest. The dose range of test item used was 0, 2, 4, 8, 16, 24 and 32 µg/ml. - Vehicle / solvent:
- Tetrahydrofuran
Justification for choice of solvent/vehicle:
The test item was accurately weighed, suspended in tetrahydrofuran (THF) and serial dilutions prepared. The molecular weight of the test item was provided by the Sponsor and was greater than 500. The test item was insoluble or non-suspendable in dimethyl sulphoxide at 100, 125, 250 and 500 mg/ml, insoluble in MEM at 50 mg/ml, insoluble at 100, 125, 250 and 500 mg/ml in acetone and insoluble in THF at 100 and 500 mg/ml. However, the test item was an emulsion in THF at 500 mg/ml, therefore, the maximum dose level was 500 µg/ml (the maximum achievable dose level). THF is toxic to human lymphocytes at and above 50 µl; therefore, the test item formulations were dosed using 50 µl aliquots. The purity of the test item was 95% and, therefore, an allowance was made when dose formulations were prepared.
Controlsopen allclose all
- Untreated negative controls:
- no
- Remarks:
- THF
- Negative solvent / vehicle controls:
- yes
- Remarks:
- THF
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- In the presence of S9
Migrated to IUCLID6: CP
- Untreated negative controls:
- no
- Remarks:
- THF
- Negative solvent / vehicle controls:
- yes
- Remarks:
- THF
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- In the absence of S9
Migrated to IUCLID6: MMC
- Details on test system and experimental conditions:
- METHODS OF APPLICATION:
In medium
DURATION
- Pre-incubation period:
48 hours
- Exposure duration:
Experiment 1 – 4 hours with and without S9. Experiment 2 – 24 hours without S9, 4 hours with S9.
- Expression time (cells in growth medium):
20 hours for 4 hours exposure
- Selection time (in incubation with a selective agent):
Not applicable
- Fixation time (start of exposure up to fixation or harvest of cells):
24 hours
SELECTION AGENT (MUTATION ASSAYS):
No selection agent selected
SPINDLE INHIBITOR (Cytogenetic assays):
Demecolcine
STAIN (for cytogenetic assays):
When slides were dry they were stained in 5% giemsa for 5 minutes, rinsed, dried and coverslipped using mounting medium.
NUMBER OF REPLICATIONS:
Duplicate cultures
NUMBER OF CELLS EVALUATED:
100/culture
DETERMINATION OF CYTOTOXICITY
-Method:
Mitotic index – A total of 2000 lymphocyte cell nuclei were counted and the number of cells in metaphase recorded and expressed as the mitotic index as a percentage of the vehicle control value.
-Scoring of Chromosome Damage:
Where possible the first 100 consecutive well-spread metaphases from each culture were counted, where there were approximately 30 to 50% of cells with aberrations, slide evaluation was terminated at 50 cells. If the cell had 44-48 chromosomes, any gaps, breaks or rearrangements were noted according to the simplified system of Savage (1976) recommended in the 1983 UKEMS guidelines for mutagenicity testing (Appendix 1). Cells with chromosome aberrations were reviewed as necessary by a senior cytogeneticist prior to decoding the slides.
OTHER EXAMINATIONS:
- Determination of polyploidy:
Frequency of polyploid cells
OTHER:
nonE - Evaluation criteria:
- A positive response was recorded for a particular treatment if the % cells with aberrations, excluding gaps, markedly exceeded that seen in the concurrent control, either with or without a clear dose-relationship. For modest increases in aberration frequency a dose response relationship is generally required and appropriate statistical tests may be applied in order to record a positive response.
- Statistics:
- The frequency of cells with aberrations excluding gaps and the frequency of polyploid cells was compared, where necessary, with the concurrent vehicle control value using Fisher's Exact test.
Results and discussion
Test results
- Species / strain:
- lymphocytes: Human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Preliminary Toxicity Test (Cell Growth Inhibition Test)
The dose range for the Preliminary Toxicity Test was 2.0 to 500 µg/ml. The molecular weight of the test item was greater than 500. However, the test item was not soluble in any of the acceptable vehicles to dose at 5000 µg/ml, therefore the maximum practical dose level was 500 µg/ml. A precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure, initially at and above 2.0 and 3.9 µg/ml, in the absence and presence of S9, in the 4(20)-hour cultures, respectively. A precipitate of the test item was observed in the parallel blood-free cultures at the end of the continuous exposure period at and above 3.9 µg/ml. It should be noted that in the absence of S9 the precipitate aggregated at and above 15.62 µg/ml, effectively reducing exposure of the test item to the cells.
Microscopic assessment of the slides prepared from the exposed cultures showed that metaphase cells suitable for scoring were present up to 500 µg/ml in all of the exposure groups. There was some evidence of modest reductions in mitotic index in all of the exposure groups at the upper dose levels in the 4(20)-hour cultures, whilst no clear dose relationship was observed, it was apparent that maximum exposure was occurring at and around 31.25 µg/ml. The mitotic index data are presented in Table 1.
Therefore the selection of the maximum dose levels for the exposure groups was based on the onset of marked precipitating dose levels for all exposure groups in both experiments and the apparent maximum exposure occurring at and around 31.25 µg/ml.
Chromosome Aberration Test – Experiment 1
The dose levels of the controls and the test item are given in the table below:
Group Final concentration of Diurea thickener 8 (µg/ml)
4(20)-hour without S9 0*, 2, 4*, 8, 16*, 24, 32*, MMC 0.4*
4(20)-hour with S9 0*, 2, 4*, 8, 16*, 24, 32*, CP 5*
*: dose levels selected for metaphase analysis
The qualitative assessment of the slides determined that test item induced precipitate was similar to that observed in the Preliminary Toxicity Test and that there were metaphases suitable for scoring present at the maximum dose level of test item, 32 µg/ml, in the absence and presence of metabolic activation (S9). A precipitate of the test item was observed at the end of exposure at and above 4 and 8 µg/ml in the absence and presence of S9 in the whole blood cultures. No media only cultures were employed for precipitate assessment.
The mitotic index data are given in Table 2. They confirm the qualitative observations in that no marked or dose-related inhibition of mitotic index was observed in the absence of S9 with 13% mitotic inhibition at 32 µg/ml in the presence of metabolic activation only. The maximum dose level of 32 µg/ml was selected for metaphase analysis for both exposure groups. Although the toxicity observed in the preliminary toxicity test was not reproduced, it was still considered that the test item had been adequately tested.
The chromosome aberration data are given in Table 4 and Table 5. All of the vehicle control cultures had frequencies of cells with chromosome aberrations within the expected range. All the positive control items induced statistically significant increases in the frequency of cells with aberrations indicating that the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item did not induce any statistically significant increases in the frequency of cells with aberrations either in the absence or presence of metabolic activation.
The polyploid cell frequency data are given in Table 4 and Table 5. The test item did not induce a statistically significant increase in the numbers of polyploid cells at any dose level in either of the exposure groups.
Chromosome Aberration Test – Experiment 2
The dose levels of the controls and the test item are given in the table below:
Group Final concentration of Diurea thickener 8 (µg/ml)
24-hour without S9 0*, 2, 4, 8*, 12*, 16*, 24*, MMC 0.2*
4(20)-hour with S9 0*, 2, 4*, 8*, 16*, 24*, 32, CP 5*
* :dose levels selected for metaphase analysis
The qualitative assessment of the slides determined that there were metaphases suitable for scoring present at the maximum test item dose level of 24 µg/ml in the absence of S9 and at 32 µg/ml in the presence of S9. A precipitate of the test item was observed at the end of exposure, at and above 16 µg/ml, in the presence of S9, and at 24 µg/ml in the absence of S9. Based on the above observations at least one clear precipitating dose level was selected for mitotic index evaluation.
The mitotic index data are given in Table 3. There was a modest reduction in mitotic index (35%) in the continuous exposure group (without S9) at the upper dose of 24 µg/ml. No reduction in mitotic index was observed in the in the 4(20)-hour culture (with S9).
The maximum dose level selected for metaphase analysis was 24 µg/ml in both exposure groups.
The chromosome aberration data are given in Table 6 and Table 7. All of the vehicle control cultures had frequencies of cells with chromosome aberrations within the expected range. All the positive control items induced statistically significant increases in the frequency of cells with aberrations indicating that the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item did not induce any statistically significant increases in the frequency of cells with chromosome aberrations either in the absence or presence of metabolic activation.
The polyploid cell frequency data are given in Table 6 and Table 7. The test item did not induce a statistically significant increase in the numbers of polyploid cells at any dose level in either of the exposure groups. - Remarks on result:
- other: strain/cell type:
- Remarks:
- Migrated from field 'Test system'.
Any other information on results incl. tables
See overall remarks and attachments
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
negative
Thetest item did not induce a statistically significant increase in the frequency of cells with chromosome aberrations in either the absence or presence of a liver enzyme metabolising system in either of two separate experiments. The test item was therefore considered to be non-clastogenic to human lymphocytes in vitro. - Executive summary:
Introduction.
This report describes the results of an in vitro study for the detection of structural chromosomal aberrations in cultured mammalian cells. It supplements microbial systems insofar as it identifies potential mutagens that produce chromosomal aberrations rather than gene mutations (Scott et al, 1990). The method was designed to be compatible with the OECD Guidelines for Testing of Chemicals (1997) No. 473 "Genetic Toxicology: Chromosome Aberration Test" and Method B10 of Commission Regulation (EC) No. 440/2008 of 30 May 2008. The study design was also compatible with the UK Department of Health Guidelines for Testing of Chemicals for Mutagenicity.
Methods.
Duplicate cultures of human lymphocytes, treated with the test item, were evaluated for chromosome aberrations at up to four dose levels, together with vehicle and positive controls. Four treatment conditions were used for the study, i.e. In Experiment 1, 4 hours in the presence of an induced rat liver homogenate metabolising system (S9), at a 2% final concentration with cell harvest after a 20-hour expression period and a 4 hours exposure in the absence of metabolic activation (S9) with a 20-hour expression period. In Experiment 2, the 4 hours exposure with addition of S9 was repeated (using a 1% final S9 concentration), whilst in the absence of metabolic activation the exposure time was increased to 24 hours.
The dose levels used in Experiments 1 and 2 were selected using data from the preliminary toxicity test and were as follows:
Experiment
Group
Final concentration of test item (µg/ml)
1
4(20)-hour without S9
2, 4, 8, 16, 24 and 32
4(20)-hour with S9 (2%)
2, 4, 8, 16, 24 and 32
2
24-hour without S9
2, 4, 8, 12, 16 and 24
4(20)-hour with S9 (1%)
2, 4, 8, 16, 24 and 32
Results.
All vehicle (solvent) controls had frequencies of cells with aberrations within the range expected for normal human lymphocytes.
All the positive control items induced statistically significant increases in the frequency of cells with aberrations indicating that the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item was considered to be only moderately toxic and did not induce any statistically significant increases in the frequency of cells with aberrations, in either of two separate experiments, using a dose range that included a dose level that was the lowest precipitating dose level.
Conclusion. The test item was considered to be non-clastogenic to human lymphocytes in vitro.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Embora a ECHA disponibilize muito material em linha na sua língua, uma parte desta página está disponível apenas em inglês. Mais informações sobreas práticas de multilinguismo da ECHA.
Bem-vindo ao sítio Web da ECHA O navegador Internet Explorer 7 (e versões anteriores) não é totalmente suportado por este sítio Web. Por favor atualize o seu Internet Explorer para uma versão mais recente.
Este sítio Web utiliza cookies a fim de garantir a melhor experiência possível nos nossos sítios Web.
Saiba mais sobre como utilizar cookies.